poisar

Stocks · News reference

Leerink Partners Initiates Coverage On Shattuck Labs with Outperform Rating, Announces Price Target of $16

Jul 20, 2026, 4:26 PMBenzinga Newsdesk

Leerink Partners analyst Faisal Khurshid initiates coverage on Shattuck Labs (NASDAQ:STTK) with a Outperform rating and announces Price Target of $16.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

STTK
Source
benzinga
Observed
Jul 20, 2026, 4:26 PM
Checked
Jul 20, 2026, 4:26 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 24, 2026, 10:03 PMEric Volkman

    What Shattuck Labs Stock Topped the Market on Monday

    Shattuck Labs (STTK) gained nearly 5% on Monday following positive analyst coverage from two firms. TD Cowen initiated a buy rating while Raymond James issued a strong buy with an $18 price target (more than double the $7.90 closing price). The optimism centers on the company's lead drug candidate SL-325, a first-in-class autoimmune and inflammatory disease treatment currently in Phase 2b clinical testing for inflammatory bowel disease, with analysts estimating a $20+ billion addressable market.

    Read original at the-motley-fool
    STTK